INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 74 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2015. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2016 | $5,132,000 | -86.4% | 336,759 | -65.3% | 0.41% | -88.7% |
| Q2 2016 | $37,716,000 | +28.5% | 971,565 | -8.0% | 3.60% | +19.9% |
| Q1 2016 | $29,358,000 | -55.4% | 1,056,059 | -13.7% | 3.00% | -39.0% |
| Q4 2015 | $65,824,000 | +24.3% | 1,223,717 | -7.5% | 4.93% | +22.8% |
| Q3 2015 | $52,957,000 | +171.6% | 1,322,592 | +116.8% | 4.01% | +151.1% |
| Q2 2015 | $19,495,000 | +22.1% | 610,171 | -8.7% | 1.60% | +11.4% |
| Q1 2015 | $15,968,000 | -8.7% | 668,671 | -32.5% | 1.43% | -24.7% |
| Q4 2014 | $17,488,000 | +27.1% | 990,810 | -1.3% | 1.90% | +19.8% |
| Q3 2014 | $13,758,000 | -16.7% | 1,003,496 | +2.5% | 1.59% | -20.7% |
| Q2 2014 | $16,513,000 | -9.3% | 979,446 | -2.2% | 2.00% | -7.8% |
| Q1 2014 | $18,199,000 | – | 1,001,060 | – | 2.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |